Magram has over 20 years of drug discovery and development experience. She was the founding chief scientific officer of Northern Biologics, a Toronto Canada based biotechnology company. Prior to Northern Biologics, she served as the site head for Pfizer's Centers for Therapeutic Innovation, New York.
Previously, Magram was vice president, immunology and inflammation research at Boehringer Ingelheim, overseeing a department committed to drug discovery to address unmet medical needs in autoimmune disease.
Prior to Boehringer Ingelheim, she was an associate director of G protein-coupled receptor drug discovery at OSI Pharmaceuticals. She also previously spent over five years at Hoffmann-La Roche focused on using model systems to understand the pathophysiology of disease and to identify new therapies.
Magram completed her postdoctoral training in the laboratory of Nobel Laureate J. Michael Bishop, M.D. at the University of California, San Francisco School of Medicine and obtained her Ph.D. in the laboratory of Franklin Costantini, Ph.D. in the Department of Genetics and Development at Columbia University Irving Medical Center.
Privately held Quentis Therapeutics is pursuing first-in-class endoplasmic reticulum stress response-targeted therapies to address serious diseases such as cancer.
The company is pioneering the use of ER stress response modulators to boost the immune system's ability to fight cancer and to help more cancer patients benefit from immunotherapy. Its lead program is a first-in-class, small molecule, IRE1α inhibitor.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886